PLK1 and gastric cancer: Similar results were observed using the dual WEE1 and Polo-like kinase 1 (PLK1) inhibitor AZD1775 in gastric cancer cells, which disrupted HR repair and the DNA damage checkpoint, as well as sensitized HR-proficient cells to Olaparib [69].